Figure S2.
Epitope peptide and restricting HLAs of clonotype-017/018.(A) Relative positions within the S protein that are covered by each S peptide pool are shown. Strong binding peptides (%RANK ≤2) presented by DRA-DRB1*15:01 in regions 633–682, 708–740, 771–784, and 803–884 (pink regions) were predicted using NetMHC 4.0 Server. 19-mer peptides (red bars) that cover the strong binding peptides were synthesized and used for further epitope identification. (B) Cells expressing TCR-017 or -018 were stimulated with 1 μg/ml of S peptide pool #2 in the presence of heterologous APCs from exchanged donors (Ts-018 and Ts-017, respectively). (C) Cells expressing TCR-017 or -018 were stimulated with 1 μg/ml of peptide S864–882 in the presence of HEK293T cells expressing the indicated HLAs. Data are representative of two independent experiments (B and C). NTD, N-terminal domain; FP, fusion peptide; TM, transmembrane domain.

Epitope peptide and restricting HLAs of clonotype-017/018. (A) Relative positions within the S protein that are covered by each S peptide pool are shown. Strong binding peptides (%RANK ≤2) presented by DRA-DRB1*15:01 in regions 633–682, 708–740, 771–784, and 803–884 (pink regions) were predicted using NetMHC 4.0 Server. 19-mer peptides (red bars) that cover the strong binding peptides were synthesized and used for further epitope identification. (B) Cells expressing TCR-017 or -018 were stimulated with 1 μg/ml of S peptide pool #2 in the presence of heterologous APCs from exchanged donors (Ts-018 and Ts-017, respectively). (C) Cells expressing TCR-017 or -018 were stimulated with 1 μg/ml of peptide S864–882 in the presence of HEK293T cells expressing the indicated HLAs. Data are representative of two independent experiments (B and C). NTD, N-terminal domain; FP, fusion peptide; TM, transmembrane domain.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal